| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J. Biol. Chem., Vol. 266, Issue 22, 14300-14305, Aug, 1991
GK Scott, JM Dodson, PA Montgomery, RM Johnson, JC Sarup, WL Wong, A Ullrich, HM Shepard and CC Benz
Cancer Research Institute, University of California, San Francisco 94143.
A partially agonistic monoclonal antibody, 4D5, known to bind to the extracellular domain of p185HER2 and shown to inhibit long term growth of p185HER2-overexpressing breast cancer cells, was used to study signal transduction and phosphotyrosyl protein substrates associated with this receptor. Normal breast epithelial cells and breast carcinoma cells expressing low levels of p185HER2 were not affected by 4D5. HER2/neu-overexpressing breast cancer cells (BT-474 and SK-Br-3) exposed to 4D5 exhibited rapid phosphorylation of both p185HER2 and an associated 56-kDa phosphotyrosyl protein (ptyr56). Paralleling the 4D5- stimulated phosphorylation of p185HER2 and ptyr56 was a 5-10-fold induction of c-fos mRNA and phosphatidylinositol 4-kinase activity and a 2-fold induction of inositol 1,4,5-trisphosphate 3'-kinase activity. The increased phosphatidylinositol 4-kinase activity immunoprecipitated with p185HER2 and also co-eluted with ptyr56 from an antiphosphotyrosine immunoaffinity column. These results indicate that short term (less than 6 h) 4D5 activation of p185HER2 in overexpressing breast cancer cells produces agonistic-like signaling typical of homologous tyrosine kinase growth factor receptors such as epidermal growth factor receptor. The data also suggest that ptyr56 represents a novel phosphorylated substrate associated with 4D5-stimulated p185HER2.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  C. A. Ritter, M. Perez-Torres, C. Rinehart, M. Guix, T. Dugger, J. A. Engelman, and C. L. Arteaga Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network Clin. Cancer Res., August 15, 2007; 13(16): 4909 - 4919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-H. Huang and S. L. Morrison A Trimeric Anti-HER2/neu ScFv and Tumor Necrosis Factor-{alpha} Fusion Protein Induces HER2/neu Signaling and Facilitates Repair of Injured Epithelia J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 983 - 991. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Austin, A. M. De Maziere, P. I. Pisacane, S. M. van Dijk, C. Eigenbrot, M. X. Sliwkowski, J. Klumperman, and R. H. Scheller Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin Mol. Biol. Cell, December 1, 2004; 15(12): 5268 - 5282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Bergman, M. A. Barmada, J. A. Griffin, and D. J. Slamon Treatment of Meningeal Breast Cancer Xenografts in the Rat Using an Anti-P185/HER2 Antibody Clin. Cancer Res., July 1, 2001; 7(7): 2050 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Lane, I. Beuvink, A. B. Motoyama, J. M. Daly, R. M. Neve, and N. E. Hynes ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency Mol. Cell. Biol., May 1, 2000; 20(9): 3210 - 3223. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. Adam, R. Vadlamudi, S. B. Kondapaka, J. Chernoff, J. Mendelsohn, and R. Kumar Heregulin Regulates Cytoskeletal Reorganization and Cell Migration through the p21-activated Kinase-1 via Phosphatidylinositol-3 Kinase J. Biol. Chem., October 23, 1998; 273(43): 28238 - 28246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-A. Ghetie, E. M. Podar, A. Ilgen, B. E. Gordon, J. W. Uhr, and E. S. Vitetta Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells PNAS, July 8, 1997; 94(14): 7509 - 7514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Reese and D. J. Slamon HER-2/neu Signal Transduction in Human Breast and Ovarian Cancer Stem Cells, January 1, 1997; 15(1): 1 - 8. [Abstract] [Full Text]
|
|
|
|
|
|
C. K. Galang, J. J. García-Ramírez, P. A. Solski, J. K. Westwick, C. J. Der, N. N. Neznanov, R. G. Oshima, and C. A. Hauser Oncogenic Neu/ErbB-2 Increases Ets, AP-1, and NF-kappaB-dependent Gene Expression, and Inhibiting Ets Activation Blocks Neu-mediated Cellular Transformation J. Biol. Chem., April 5, 1996; 271(14): 7992 - 7998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. H. Chan, D. M. Antoniucci, K. S. Fok, M. L. Alajoki, R. N. Harkins, S. A. Thompson, and H. G. Wada Heregulin Activation of Extracellular Acidification in Mammary Carcinoma Cells Is Associated with Expression of HER2 and HER3 J. Biol. Chem., September 22, 1995; 270(38): 22608 - 22613. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. E. Holmes, M. X. Sliwkowski, R. W. Akita, W. J. Henzel, J. Lee, J. W. Park, D. Yansura, N. Abadi, H. Raab, G. D. Lewis, et al. Identification of Heregulin, a Specific Activator of p185erbB2 Science, May 22, 1992; 256(5060): 1205 - 1210. [Abstract] [PDF]
|
|
|
|
|
|
G. Levkowitz, S. Oved, L. N. Klapper, D. Harari, S. Lavi, M. Sela, and Y. Yarden c-Cbl Is a Suppressor of the Neu Oncogene J. Biol. Chem., November 3, 2000; 275(45): 35532 - 35539. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
